Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritisIL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritisCirculating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical responseIncreased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytesClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseInterleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritisAnatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synoviumOverexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatmentInterleukin-17 and type 17 helper T cellsRegulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritisImportance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritisApolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritisRole of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression.Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritisIL-17 as a future therapeutic target for rheumatoid arthritis.Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymesIL-17 in Chronic Inflammation: From Discovery to Targeting.Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy.The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis populationRheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope.An update on the cytokine network in rheumatoid arthritis.A Feedback Loop between Inflammation and Zn Uptake.IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors.A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.The role of T cells in rheumatoid arthritis: new subsets and new targets.Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified.Cytokine response in inflammatory myopathies.Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis.Physiopathology of haemophilic arthropathy.IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion.Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium.Chemokines and dendritic cells in inflammatory myopathies.IL-17 and Th17 cells in human inflammatory diseases.Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis.Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis.Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes.Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
P50
Q24792962-E78C5230-99CE-4E73-963F-0EBB442EC40EQ24796707-E09DEB5B-E50C-4F5B-BBAB-EB4411F86426Q24799187-352FFC0A-8D76-4D54-86BB-A2B12ADB7416Q24800545-D1DEF90E-6A0E-4EDC-925B-BBDFEB7244CEQ26753120-10200CE3-ACF8-4F08-93A6-1D0A585AC9F8Q27023777-0B53B8F9-BF9B-4863-A716-B680C8EF768CQ28216812-988EE81C-9876-4A6A-B6A6-A15C84F7C23AQ28248671-B1F63B78-581E-4A74-A292-7C0EE35F55B8Q28256510-014B182A-D3C5-480C-960E-A99580C83924Q28266123-304889FC-1442-4766-A75C-80284F5E90C1Q28743723-B6CBEBEF-CD98-4479-8D52-7D1660100976Q33355906-ADA1DB05-7088-4367-A11E-D268BA32797AQ33728533-2C2F3E9B-40CF-4070-B744-88055518B784Q33729159-32CE7A2C-7E3C-4644-8D3B-DA7D69030225Q34019620-BAFEF66E-D286-4C33-9E53-2CCDACF42BDAQ34153004-DDC97970-2470-4BBB-908B-1851C22B9E18Q34512003-97FC9955-0598-4034-99BF-08F4BB6307A2Q35083970-511AB085-62F1-4A49-A3E5-E747BA6F33E1Q35636836-B71F3B5C-6BAC-4B4D-976B-4870B2C9709FQ35638646-5E795006-6AA8-4382-9C0E-5FCB7969BE5EQ35753674-B08E638D-3886-4289-845E-6C1589F9A6C7Q35914585-45C60316-D45F-44D6-A347-DBACA8362CEBQ35954465-A60F73D1-AEBC-481C-BAE2-06741D2FEF1CQ36392269-20FEDE69-111A-4B36-929E-162C03DAEC98Q36784042-205B97C9-02FF-4092-B90B-6DC312996C3EQ36864379-15E00A62-4642-4D5C-9B33-266837270F0CQ36905988-DFB6E9B4-DAD8-4ED7-9945-1A1CEAD263EFQ36907680-FDC75555-26A2-49D6-BD73-6C0CDE4546A6Q37169661-9EF5BBE6-60B3-4939-BA82-FFD517915253Q37202023-8BF3B769-A23B-4E44-85D6-A6721101670BQ37204634-2D1EE6C2-0DBB-456F-93E1-EA97260F03BBQ37307876-8E58ED83-F111-46D3-BFF8-BDE3226D2A4CQ37324843-A00D23B6-6930-497B-B78C-B4A7015C4BBAQ37391814-320BEF0B-F6C4-4A3B-AAD1-0E23960960C2Q37446159-413DDEAF-645C-4857-8451-D3A1EFD49805Q37453953-69184709-6BCE-4751-ACD4-C4AD282954EDQ37728316-59F1961E-080A-492D-83D0-CE07BD14E506Q37755850-FEF44B59-D929-4059-B099-F8023DE965B8Q37846348-825892E2-AD27-4763-9817-ED06B4CACBEEQ37904498-F75058BA-B41A-4B1A-8694-766C038B29CB
P50
description
dokter asal Perancis
@id
médecin français
@fr
médicu francés
@ast
name
Pierre Miossec
@ast
Pierre Miossec
@ca
Pierre Miossec
@en
Pierre Miossec
@es
Pierre Miossec
@fr
Pierre Miossec
@sl
type
label
Pierre Miossec
@ast
Pierre Miossec
@ca
Pierre Miossec
@en
Pierre Miossec
@es
Pierre Miossec
@fr
Pierre Miossec
@sl
prefLabel
Pierre Miossec
@ast
Pierre Miossec
@ca
Pierre Miossec
@en
Pierre Miossec
@es
Pierre Miossec
@fr
Pierre Miossec
@sl
P1015
P214
P244
P268
P269
P5361
P1015
P106
P19
P21
P213
0000 0000 8371 1756
P214
P244
P268
P269
P27
P31
P3956
P4124
pierre-miossec_67733